Abgentis News

  • Low spontaneous resistance development to GYR12/colistin combination

    Abgentis continues to explore the potential of the novobiocin-analogue GYR12 in combination with antibiotic potentiators such as colistin, polymixin B or pentamidine.

    At pharmacologically achievable exposures GYR12/colisitin has broad-spectrum activity including E. coli, K. pneumoniae, A. baumannii and P. aeruginosa.

    We have recently shown that spontaneous resistance frequency development to the combination is low e.g. <10e-9, consistent with suppression of resistance in use.

    The combination of GYR12 with a potentiator such as colistin or pentamidine has the potential to bring the GyrB/ParE targets into clinical use to treat drug-resistant Gram-ve bacterial infections.


Abgentis News

You are viewing the text version of this site.

To view the full version please install the Adobe Flash Player and ensure your web browser has JavaScript enabled.

Need help? check the requirements page.

Get Flash Player